Not Yet RecruitingPhase 2

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

79 participantsStarted 2026-05

Plain-language summary

The goal of this study is to determine the efficacy of the study drugs tovorafenib to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (MAPK) that this drug targets. The main question the study aims to answer is whether tovorafenib can prolong the life of patients diagnosed with HGG, including DIPG.

Who can participate

Age range12 Months – 39 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age Patients must be ≥12 months and ≤39 years of age at the time of enrollment on TarGeT-SCR.
✓. Body Surface Area (BSA) Patients must have a BSA \>0.3m2.
✓. Diagnosis:
✓. Disease Status
✓. TarGeT-B Strata Definitions
✓. Presence of at least one relevant actionable somatic alteration:
✓. Performance Level:
✓. Prior Therapy for HGG:

Exclusion criteria

✕. Pregnancy or breastfeeding.
✕. Other Exclusion Criteria
✕. Concomitant Medications • Corticosteroids: Patients receiving corticosteroids are eligible, but the use of corticosteroids must be reported.

What they're measuring

Progression Free Survival Stratum A

Timeframe: 6 years

Trial details

NCT IDNCT07206849

SponsorNationwide Children's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2030-05

Contact for this trial

Kelsey H Troyer, PhD

16147223284 kelsey.troyer@nationwidechildrens.org

View on ClinicalTrials.gov More High Grade Glioma (HGG) of the Brain With BRAF Aberration trials